<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36102">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636582</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-02189</org_study_id>
    <secondary_id>NCI-2015-02189</secondary_id>
    <secondary_id>N01-CN-2012-00034</secondary_id>
    <secondary_id>2016-0164</secondary_id>
    <secondary_id>MDA2014-04-02</secondary_id>
    <secondary_id>N01CN00034</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02636582</nct_id>
  </id_info>
  <brief_title>Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer</brief_title>
  <acronym>VADIS</acronym>
  <official_title>VADIS Trial: Phase II Trial of Nelipepimut-S Peptide Vaccine in Women With DCIS of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or
      sargramostim works in treating patients with breast cancer. Vaccines made from peptide or
      antigen and/or a person's white blood cells mixed with tumor proteins may help the body
      build an effective immune response to kill tumor cells that express breast cancer. It is not
      yet known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in
      treating patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate for nelipepimut-S-specific cytotoxic T lymphocyte (CTL; cluster of
      differentiation [CD]8+ T cell) response in vaccinated patients compared to patients
      receiving GM-CSF (sargramostim) alone.

      SECONDARY OBJECTIVES:

      I. Toxicity profile and frequency of adverse events in women with ductal carcinoma in situ
      (DCIS) of the breast receiving nelipepimut-S vaccine (nelipepimut-S plus GM-CSF vaccine) as
      compared to women receiving GM-CSF alone.

      II. In vivo immune response to nelipepimut-S determined by delayed type hypersensitivity
      reaction; III. Immune response to other tumor antigens (epitope spreading). IV. Functional
      capacity of the immune response to vaccination. V. Determine CTL functional capability using
      intracellular cytokine assays. VI. Evaluate polyfunctional cytokine responses assessed by
      multiplex assay. VII. Presence of DCIS at resection. VIII. Difference in human epidermal
      growth factor receptor 2 (HER2) expression in the biopsy and the surgical specimen excised
      post-vaccination.

      IX. Histologic responses: degree of lymphocyte infiltration determined on hematoxylin and
      eosin (H&amp;E) stained slides and by immunohistochemistry staining for CD3, CD4 and CD8.

      X. Histologic responses: proliferation-related Ki-67 antigen (Ki67) in DCIS cells
      (proliferation).

      XI. Histologic responses: cleaved caspase 3 in DCIS cells (apoptosis). XII. Immune
      infiltrates in normal tissue maximally distant from the tumor (in mastectomy samples).

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive nelipepimut-S plus GM-CSF vaccine intradermally (ID) 3 vaccination 2
      weeks apart prior to surgery.

      ARM II: Patients receive sargramostim ID 3 vaccinations 2 weeks apart prior to surgery, and
      3 vaccinations 1 months apart post-surgery.

      After completion of study treatment, patients are followed up at 1 and 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of nelipepimut-S-cytotoxic T lymphocytes (CTL), detected using a dextramer assay</measure>
    <time_frame>Pre-vaccination to up to 1 month after surgery</time_frame>
    <description>Change of nelipepimut-S-specific CTL at the 1 month (+/- 7 days) after completion of the vaccination series timepoint from baseline will be estimated for each group using mean, standard deviation, median, minimum and maximum. Two-sample t-test or Wilcoxon rank sum test, whichever appropriate, will be used to compare the change between the two groups. Nelipepimut-S-specific CTL will also be measured repeatedly through 6 months after the last vaccination. Repeated measures analysis including mixed effects model will be performed to analyze the effect of treatment on nelipepimut-S-specific CTL ch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apoptosis as measured by cleaved caspase 3 in DCIS cells</measure>
    <time_frame>Pre-vaccination to up to surgery</time_frame>
    <description>The % positive cells in the DCIS samples from pre-treatment and post-treatment samples and a &quot;difference statistic&quot; for each participant will be calculated (the change in % positive between pre- and post-treatment sample for each participant). If the distribution of % positive values is not a normal distribution, then it may be necessary to log-transform the primary data before calculating the difference statistic. These biomarker data will be visualized by plotting each participant's pre- and post-treatment value (&quot;spaghetti plots&quot;). The average &quot;difference statistic&quot; will then be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of epitope specific-CTL</measure>
    <time_frame>Pre-vaccination to up to 3 months after surgery at the time of the final study visit</time_frame>
    <description>Evidence of inter-antigenic epitope spreading will be evaluated by quantifying the number of CTL specific for the folate binding protein derived epitope E39 (EIWTHSYKV) and the cyclin E-derived epitope CCNE144-152 (ILLDWLMEV). The association among various continuous and discrete biomarkers or treatment groups will be assessed by the exploratory data analysis using scatter plot matrix, box plots, BLiP plot and trellis plot, etc., and may be tested by t-test/analysis of variance (ANOVA)/Wilcoxon rank sun test/Kruskal-Wallis test, when appropriate. Correlation between continuous biomarkers will</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTL functional capability, measured using intracellular cytokine assays</measure>
    <time_frame>Up to 3 months after completion of the vaccination series timepoint</time_frame>
    <description>The association among various continuous and discrete biomarkers or treatment groups will be assessed by the exploratory data analysis using scatter plot matrix, box plots, BLiP plot and trellis plot, etc., and may be tested by t-test/ANOVA/Wilcoxon rank sun test/Kruskal-Wallis test, when appropriate. Correlation between continuous biomarkers will be examined by Pearson or Spearman rank correlation coefficients. The association between discrete biomarkers will be tested by chi-square or Fisher's exact test. Paired t-test/Wilcoxon rank sum test and McNemar's test may be used to test the change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of lymphocyte infiltration</measure>
    <time_frame>Pre-vaccination to up to surgery</time_frame>
    <description>Intra-tumoral and stromal tumor infiltrating lymphocytes will be scored as a continuous variable and the percentage of in the surgical specimen will be compared to that in the pre-vaccination diagnostic biopsy. The association among various continuous and discrete biomarkers or treatment groups will be assessed by the exploratory data analysis using scatter plot matrix, box plots, BLiP plot and trellis plot, etc., and may be tested by t-test/ANOVA/Wilcoxon rank sun test/Kruskal-Wallis test, when appropriate. Correlation between continuous biomarkers will be examined by Pearson or Spearman rank</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in HER2 expression in the biopsy and the surgical specimen excised post-vaccination</measure>
    <time_frame>Pre-vaccination to up to surgery</time_frame>
    <description>HER2 scoring will be determined according to the American Society of Clinical Oncology/College of American Pathologists clinical guidelines. Pre-vaccination and post-vaccination specimens will be compared. The association among various continuous and discrete biomarkers or treatment groups will be assessed by the exploratory data analysis using scatter plot matrix, box plots, BLiP plot and trellis plot, etc., and may be tested by t-test/ANOVA/Wilcoxon rank sun test/Kruskal-Wallis test, when appropriate. Correlation between continuous biomarkers will be examined by Pearson or Spearman rank corr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune infiltrates in normal tissue maximally distant from the tumor (in mastectomy samples)</measure>
    <time_frame>At surgery</time_frame>
    <description>The association among various continuous and discrete biomarkers or treatment groups will be assessed by the exploratory data analysis using scatter plot matrix, box plots, BLiP plot and trellis plot, etc., and may be tested by t-test/ANOVA/Wilcoxon rank sun test/Kruskal-Wallis test, when appropriate. Correlation between continuous biomarkers will be examined by Pearson or Spearman rank correlation coefficients. The association between discrete biomarkers will be tested by chi-square or Fisher's exact test. Paired t-test/Wilcoxon rank sum test and McNemar's test may be used to test the change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune infiltration as determined by immunohistochemistry staining for CD3, CD4 and CD8</measure>
    <time_frame>Pre-vaccination to up to surgery</time_frame>
    <description>Total number of positive cells for each immune cell marker in 10 high power fields in the DCIS samples from pre-treatment and post-treatment samples will be counted and a &quot;difference statistic&quot; for each participant will be calculated (the change in the total number of marker-positive infiltrating immune cells in the pre- and post-treatment samples for each participant). These biomarker data will be visualized by plotting each participant's pre- and post-treatment value (&quot;spaghetti plots&quot;). The average &quot;difference statistic&quot; will then be calculated for the HER2 vaccine-treated group and the GM-</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo immune response to nelipepimut-S determined by delayed type hypersensitivity reaction</measure>
    <time_frame>Up to 1 months after surgery</time_frame>
    <description>For each patient, pre- and post-vaccination DTH measurements will be compared. DTH data will be presented as means Â± standard errors and compared (pre- vs post-vaccination) using a Student t test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded according to NCI CTCAE v 4.03</measure>
    <time_frame>Up to 3 months after surgery</time_frame>
    <description>Adverse events by grade and relationship will be summarized by tabulation for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyfunctional cytokine responses assessed by multiplex assays</measure>
    <time_frame>Up to 3 months after completion of the vaccination series timepoint</time_frame>
    <description>A standard curve will be generated for each cytokine and the cytokine concentration in individual patient samples will be determined by comparison to that standard curve. The association among various continuous and discrete biomarkers or treatment groups will be assessed by the exploratory data analysis using scatter plot matrix, box plots, BLiP plot and trellis plot, etc., and may be tested by t-test/ANOVA/Wilcoxon rank sun test/Kruskal-Wallis test, when appropriate. Correlation between continuous biomarkers will be examined by Pearson or Spearman rank correlation coefficients. The associati</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of DCIS at resection</measure>
    <time_frame>At surgery</time_frame>
    <description>The histologic data will be presented in tabular form to examine whether the vaccine treatment is associated with the absence of DCIS, induction of necrosis, reduction in histologic grade, or a reduction in the size of DCIS. These data will be descriptive only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proliferation as measured by Ki67 staining in DCIS cells</measure>
    <time_frame>Pre-vaccination to up to surgery</time_frame>
    <description>The % Ki67-positive cells in the DCIS samples from pre-treatment and post-treatment samples and a &quot;difference statistic&quot; for each participant will be calculated (the change in % Ki67 between pre- and post-treatment sample for each participant). If the distribution of % Ki67 values is not a normal distribution, then it may be necessary to log-transform the primary % Ki67 data before calculating the difference statistic. These biomarker data will be visualized by plotting each participant's pre- and post-treatment value (&quot;spaghetti plots&quot;). The average &quot;difference statistic&quot; will then be calcula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.03</measure>
    <time_frame>Up to 3 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Ductal Breast Carcinoma In Situ</condition>
  <arm_group>
    <arm_group_label>Arm I (nelipepimut-S plus GM-CSF vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nelipepimut-S plus GM-CSF vaccine ID 3 vaccination 2 weeks apart prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (sargramostim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim ID 3 vaccinations 2 weeks apart prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (nelipepimut-S plus GM-CSF vaccine)</arm_group_label>
    <arm_group_label>Arm II (sargramostim)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelipepimut-S Plus GM-CSF Vaccine</intervention_name>
    <description>Given ID</description>
    <arm_group_label>Arm I (nelipepimut-S plus GM-CSF vaccine)</arm_group_label>
    <other_name>E75 Plus GM-CSF</other_name>
    <other_name>E75 Vaccine Plus GM-CSF</other_name>
    <other_name>HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF</other_name>
    <other_name>Nelipepimut-S Plus Sargramostim</other_name>
    <other_name>NeuVax Plus GM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Given ID</description>
    <arm_group_label>Arm II (sargramostim)</arm_group_label>
    <other_name>23-L-Leucinecolony-Stimulating Factor 2</other_name>
    <other_name>DRG-0012</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
    <other_name>Sagramostim</other_name>
    <other_name>Sargramostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a diagnosis of DCIS made by core needle biopsy

          -  Participants must have an area of radiographic abnormality measuring at least 1 cm

          -  Participants must be human leukocyte antigen (HLA)-A2 positive

          -  Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1
             (Karnofsky &gt;= 60%)

          -  Absolute neutrophil count &gt;= 1,500/mm^3

          -  Platelets &gt;= 100,000/mm^3

          -  Hemoglobin &gt;= 10 g/dL

          -  Blood urea nitrogen =&lt; 2 x upper limit of normal (ULN)

          -  Alkaline phosphatase =&lt; 2 x ULN

          -  Lactate dehydrogenase =&lt; 2 x ULN

          -  Creatinine =&lt; 2 x ULN

          -  Bilirubin =&lt; 2 x ULN

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 1.5 x ULN

          -  Willingness to comply with all study interventions and follow-up procedures

          -  A normal ejection fraction, as defined by the participant's institution; only limited
             echocardiograms (echos) will be used as cardiac evaluation; no other tests are
             allowed; ECHO is to be done only in HLA-A2 positive participants

          -  The ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Bilateral breast malignancy or an unconfirmed, nonmalignant but suspicious mass in
             the opposite breast to include atypical ductal hyperplasia

          -  Invasive breast cancer

          -  History of prior breast cancer

          -  History of prior ductal carcinoma in situ (DCIS); prior lobular carcinoma in situ
             (LCIS) is allowed

          -  Pregnant, unwilling to use adequate contraception during study treatment duration or
             breastfeeding; pregnant women will be excluded; women of child-bearing potential must
             agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry and for the duration of study participation OR be
             post-menopausal defined as any one of the following 1) prior hysterectomy, 2) absence
             of menstrual period for 1 year in the absence of prior chemotherapy or 3) absence of
             menstrual period for 2 years in women with a prior history of chemotherapy exposure
             who were pre-menopausal prior to chemotherapy; should a woman become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             study physician immediately

          -  Any autoimmune disease or other medical condition that, in the opinion of the
             investigator, would compromise the subject's safety

          -  Immune deficiency diseases such as immunoglobulin deficiency or immunosuppressive
             therapy that might interfere with appropriate immune response

          -  Known history of or known active infection with human immunodeficiency virus (HIV),
             hepatitis B or hepatitis C

          -  Patients on chronic steroid therapy or other immunosuppressive therapy except for
             topical steroids

          -  Patients with a known hypersensitivity to GM-CSF, yeast-derived products, or any
             component of the GM-CSF product (e.g., mannitol)

          -  Concurrent treatment with other investigational agent

          -  History of non-breast malignancy within 5 years prior to randomization, except
             curatively treated superficial bladder cancer, carcinoma in situ of the cervix (stage
             0-1), and basal cell or squamous cell carcinoma of the skin

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to NeuVax

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  No recent or planned immunotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Mittendorf</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judy E. Garber</last_name>
      <phone>617-632-5770</phone>
      <email>Judy_Garber@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Judy E. Garber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Plitas</last_name>
      <phone>646-888-4587</phone>
      <email>plitasg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>George Plitas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University/Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine D. Crew</last_name>
      <phone>212-305-1732</phone>
      <email>kd59@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine D. Crew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth A. Mittendorf</last_name>
      <phone>713-792-2362</phone>
      <email>eamitten@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth A. Mittendorf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>December 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
